Search
Glyxambi-LongForm.pdf
Jardiance-LongForm.pdf
Jentadueto-LongForm.pdf
Ofev-LongForm.pdf
Pradaxa-LongForm.pdf
synjardy-XR-LongForm.pdf
Tradjenta-LongForm.pdf
Trijardy-XR-LongForm.pdf
For Your SweetHeart Survey
For Your SweetHeart | Infographic
For Your SweetHeart | Campaign Facts
biah-us-overview-for-usda
Synjardy® (empagliflozin/metformin) Factsheet | PDF
PAP Eligibility Information
State of Connecticut Information
Dress For Your Day Guidelines
PAP Program Sales Force Info Flashcard
PAP Program information
Spanish-Enrollment-Form_0.pdf
EDITABLE-Spanish-Enrollment-form_3.pdf
New retrospective data showed empagliflozin reduced A1C, body weight and markers of abdominal fat in adults with type 2 diabetes
New retrospective data showed empagliflozin reduced A1C, body weight and markers of abdominal fat in adults with type 2 diabetes
Shanghai
Shanghai serves as an important hub for all of the company’s three business areas: Human Pharma, Animal Health and Biopharmaceutical Contract Manufacturing.
U.S. FDA approves Jardiance® (empagliflozin) tablets to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease
U.S. FDA approves Jardiance® (empagliflozin) tablets to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease
OFEV® (nintedanib) Now Available in the United States
OFEV® (nintedanib) Now Available in the United States